Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAP-Targeted iCDC in Ischemic Cardiomyopathy
NCT07505199Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2026
- Primary completion
- Apr 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial in ischemic cardiomyopathy (ICM) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Dose-Limiting Toxicities at 14 days and Treatment-Emergent Adverse Events at 6 months. Started May 2026; status: recruiting.
02
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT07505199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505199.